Eyenuk, Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening, announced that it has successfully fulfilled the contract awarded by Public Health England (PHE) to use Eyenuk's EyeArt AI Eye Screening System to grade 60,000 patient image sets from 6 different National Health Service (NHS) Diabetic Eye Screening Programmes in England. Diabetic retinopathy (DR) is a vision-threatening complication of diabetes and a leading cause of preventable vision loss globally.1 In England, an estimated 4.6 million are living with diabetes, one-third of whom are at risk of developing DR. Diabetes has become a growing health concern as the number of people diagnosed with diabetes in the U.K. has more than doubled in the last 20 years.2 The U.K. has been leading the world in diabetic retinopathy screening, achieving patient uptake rates of over 80% (screening nearly 2.5 million diabetes patients annually),3 as compared with most parts of the world where typically less than half of diabetes patients receive annual eye screening.4 As a result, diabetic retinopathy is no longer the leading cause of blindness in the working age group in England.5

LOS ANGELES--(BUSINESS WIRE)-- Eyenuk, Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening, announced that it has successfully fulfilled the contract awarded by Public Health England (PHE) to use Eyenuk's EyeArt AI Eye Screening System to grade 60,000 patient image sets from 6 different National Health Service (NHS) Diabetic Eye Screening Programmes in England. Diabetic retinopathy (DR) is a vision-threatening complication of diabetes and a leading cause of preventable vision loss globally.1 In England, an estimated 4.6 million are living with diabetes, one-third of whom are at risk of developing DR. Diabetes has become a growing health concern as the number of people diagnosed with diabetes in the U.K. has more than doubled in the last 20 years.2 The U.K. has been leading the world in diabetic retinopathy screening, achieving patient uptake rates of over 80% (screening nearly 2.5 million diabetes patients annually),3 as compared with most parts of the world where typically less than half of diabetes patients receive annual eye screening.4 As a result, diabetic retinopathy is no longer the leading cause of blindness in the working age group in England.5

LOS ANGELES--(BUSINESS WIRE)--Eyenuk Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening, announced today that the Medical Retina Center and the Diabetic Retinopathy Telescreening Program of the University Eye Clinic of Genoa DINOGMI IRCCS Ospedale Policlinico San Martino, Italy has successfully expanded their diabetic retinopathy (DR) screening program by leveraging the EyeArt AI Eye Screening System. On January 17, 2020, Dr. Donatella Musetti of the Medical Retina Center at the University Eye Clinic of Genoa presented strong EyeArt results on first 712 patients at the Macula in Liguria 2020 Conference. The University Eye Clinic of Genoa is directed by Professor C.E. Traverso and is one of Italy's major cultural and scientific institutions in the Mediterranean and Northwestern Region. "Our Institution is a regional organisation committed to investing in innovation for active and healthy ageing and supporting the transfer and scaling-up of that innovation across Europe," said Massimo Nicolò, MD PhD, associate professor at the University Eye Clinic of Genoa who leads the Medical Retina Center and the Program for Diabetic Retinopathy Telescreening. "For this reason, we are recognized as Reference Site by the European Innovation Program on Active and Healthy Ageing (EIP-AHA) sponsored by the European Commission."

LOS ANGELES--(BUSINESS WIRE)--Eyenuk Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening, announced today that the EyeArt AI Eye Screening System was deployed successfully for Italy's first national prevention and diagnosis campaign for retinal and diabetic maculopathy. A total of 2,200 patients were screened at 30 centers across Italy, with more than half chosen for EyeArt AI Eye Screening. The Month of Prevention of Diabetic Retinopathy and Maculopathy was sponsored by the Italian Ministry of Health, the city of Milan and the Italian Ophthalmology Society in collaboration with the Ambrosian Ophthalmic Center (CAMO), San Raffaele Hospital and Eyenuk. In Italy, an estimated 3.2 million patients have diabetes. As many as 25% are estimated to be affected by diabetic retinopathy (DR),1 the main cause of vision impairment and blindness among working-age adults.